Every 10-Q that POLOMAR HEALTH SVCS INC (PMHS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PMHS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMHS filings page.
Polomar Health Services, Inc. reports a sharp scale-up of its compounding pharmacy business for the quarter ended June 30, 2026. Revenue rose to $1,528,705 for the quarter and $2,534,224 for the first six months of 2026, compared with very limited activity in 2025, driven by prescription fulfillment for compounded GLP‑1 therapies and other medications. Gross margin was about 61% for the quarter and 59% year‑to‑date, supporting a six‑month net income of $174,981 and positive operating cash flow of $155,682.
The balance sheet remains highly leveraged: total assets were $814,726 against liabilities of $1,871,123, leaving a stockholders’ deficit of $1,056,397 and an accumulated deficit of $13,526,169. Management explicitly concludes that substantial doubt exists about the company’s ability to continue as a going concern absent additional capital and sustained revenue growth. Revenue and receivables are highly concentrated in a single U.S. customer, CareValidate. The company also relies on several related‑party lenders and vendors, and a related party controls roughly 49% of voting power.
Governance and compensation structures are evolving: a new Executive Chairman, CFO, and independent directors were appointed, a Special Committee was formed to review related‑party acquisitions, and the equity plan’s evergreen feature was reduced. A prior merger agreement with Altanine and a Pinata IP license were terminated, and the inhaled sildenafil program under the ForHumanity agreement is in dispute; management currently views potential loss as remote. Management reports material weaknesses in internal control over financial reporting, including inadequate segregation of duties and limited GAAP/SEC expertise, and has begun remediation steps.
Polomar Health Services (PMHS) reported a net loss of $1,712,193 for the nine months ended September 30, 2025, on revenue of $16,174, and disclosed substantial doubt about its ability to continue as a going concern. Cash was $38,854 with an accumulated deficit of $4,623,356 and a stockholders’ deficit of $7,766,596. Revenue fell sharply from $37,954 in the prior-year period while operating expenses, mainly general and administrative costs of $1,588,725, remained high. The business is being repositioned from local dermatology compounding to online fulfillment of GLP-1 and men’s health drugs and relies heavily on third-party telehealth platforms. To fund operations, the company entered into multiple related-party promissory notes and issued Series A Convertible Preferred Stock. It also signed a $750,000 guaranteed-payment ForHumanity licensing deal for inhalable drugs and agreed to an Altanine merger under which Altanine holders are expected to own about 80% of the combined company.